Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib as Augmented Conditioning and Maintenance in Relapsed Multiple Myeloma
NCT03562169Phase 3Recruiting
- Sponsor
- University of Leeds
- Start
- Mar 2017
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ixazomib in multiple myeloma (MM), sponsored by University of Leeds. Started Mar 2017; status: recruiting.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03562169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03562169.